BCYC

Peers: STRO CTMX PYXS IPHA PFE TLX ADCT CATX CGEN ZYME

| Held by: IBB BBC SBIO GWX QQQS APIE MEDX IBBQ BIB PEPT

Index	-
Market Cap	187.92M
Enterprise Value	-306.92M
Income	-190.00M
Sales	61.06M
Book/sh	7.31
Cash/sh	10.12
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	288
IPO	May 23, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	3.08
P/B	0.51
P/C	0.37
P/FCF	-
EV/EBITDA	-
EV/Sales	-5.03
Quick Ratio	12.08
Current Ratio	12.08
Debt/Eq	0.03
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-2.73
EPS next Y	-2.31
EPS next Q	-0.40
EPS this Y	23.13%
EPS next Y	4.82%
EPS next 5Y	6.97%
EPS past 3/5Y	5.87% -3.36%
Sales past 3/5Y	71.38% 47.36%
EPS Y/Y TTM	22.48%
Sales Y/Y TTM	215.59%
EPS Q/Q	37.41%
Sales Q/Q	-78.68%
Earnings	Jul 30 BMO
EPS/Sales Surpr.	-25.09% -85.33%

Insider Own	9.89%
Insider Trans	-0.64%
Inst Own	63.96%
Inst Trans	-0.97%
ROA	-26.41%
ROE	-32.23%
ROIC	-36.23%
Gross Margin	91.36%
Oper. Margin	-387.53%
Profit Margin	-311.16%
SMA20	1.51%
SMA50	-3.97%
SMA200	-20.08%
Trades

Shs Outstand	50.38M
Shs Float	45.40M
Short Float	7.28%
Short Ratio	8.26
Short Interest	3.30M
52W High	9.08 -58.92%
52W Low	3.33 12.01%
Volatility	5.74% 5.70%
ATR (14)	0.20
RSI (14)	50.33
Beta	1.60
Rel Volume	0.95
Avg Volume	399.91K
Volume	42,028

Perf Week	6.27%
Perf Month	0.00%
Perf Quarter	-10.34%
Perf Half Y	-25.25%
Perf YTD	-47.32%
Perf Year	-55.01%
Perf 3Y	-78.21%
Perf 5Y	-93.37%
Perf 10Y	-
Recom	1.60
Target Price	10.14
Prev Close	3.60
Price	3.73
Change %	3.61%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Initiated	Truist	Hold	$19
Oct-31-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$11
Nov-08-24	Initiated	Stephens	Equal-Weight	$25
Sep-06-24	Initiated	RBC Capital Mkts	Outperform	$35
Aug-07-24	Downgrade	B. Riley Securities	Buy → Neutral	$33 → $28
Sep-11-23	Upgrade	B. Riley Securities	Neutral → Buy
Aug-31-22	Initiated	Cowen	Outperform
Jul-28-22	Initiated	Barclays	Overweight	$30
Jul-06-22	Resumed	Canaccord Genuity	Buy	$60
Apr-13-22	Downgrade	B. Riley Securities	Buy → Neutral	$62 → $33
Apr-07-22	Resumed	Cantor Fitzgerald	Overweight	$100 → $80
Feb-14-22	Initiated	Morgan Stanley	Equal-Weight	$60
Dec-17-21	Initiated	SVB Leerink	Outperform	$70
Dec-09-21	Initiated	Needham	Buy	$85
Sep-30-21	Initiated	B. Riley Securities	Buy	$56
Apr-20-21	Initiated	JMP Securities	Mkt Outperform	$53
Oct-12-20	Initiated	Cantor Fitzgerald	Overweight	$30
Jun-12-20	Initiated	Oppenheimer	Outperform
Apr-17-20	Initiated	H.C. Wainwright	Buy	$25
Nov-14-19	Initiated	ROTH Capital	Buy	$17

Show Previous Ratings

Jul-30-26 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results (Business Wire)
May-21-26 05:00PM	Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting (Business Wire)
Apr-30-26 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results (Business Wire)
Apr-21-26 10:31AM	Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting (Business Wire) -6.81%
Apr-20-26 07:00AM	Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026 (Business Wire)
07:00AM	Loading…
Mar-18-26 07:00AM	Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026 (Business Wire) -7.30%
Mar-17-26 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-03-26 07:00AM	Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline (Business Wire) -7.55%
Jan-12-26 07:00AM	Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026 (Business Wire)
Dec-16-25 01:00AM	Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline (Business Wire)
Nov-12-25 04:05PM	Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Oct-30-25 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results (Business Wire) +7.09%
Sep-08-25 04:05PM	Bicycle Therapeutics Strengthens Board of Directors with New Appointments (Business Wire)
12:30AM	Analysts Positive on Bicycle Therapeutics (BCYC) After Q2 Results (Insider Monkey)
Aug-08-25 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results (Business Wire)
10:15AM	Loading…
Jul-31-25 10:15AM	Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks)
Jul-02-25 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.83%
Jun-03-25 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-22-25 05:05PM	Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting (Business Wire)
May-15-25 03:00AM	Eckert & Ziegler SE (XTER:EUZ) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
May-05-25 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -18.32%
07:52AM	Is Bicycle Therapeutics plc (BCYC) the Best Small Cap Stock to Buy with the Biggest Upside Potential? (Insider Monkey)
May-02-25 02:01PM	Bicycle Therapeutics price target lowered to $15 from $40 at Barclays (TipRanks)
May-01-25 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results (Business Wire) +6.07%
Apr-29-25 07:00AM	Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025 (Business Wire)
Apr-22-25 03:47AM	Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted (Seeking Alpha) +16.24%
Apr-02-25 07:00AM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-01-25 07:00AM	Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (Business Wire) -7.54%
Mar-27-25 07:00AM	Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments (Business Wire) +5.27%
Mar-05-25 07:00AM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:00AM	Loading…
Feb-25-25 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-14-25 02:11PM	Bicycle Therapeutics (BCYC): Among The SmallCap Stocks Insiders Are Selling Recently (Insider Monkey)
Feb-05-25 07:00AM	Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Feb-03-25 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.45%
Jan-13-25 07:00AM	Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones (Business Wire) +13.90%
Jan-09-25 07:00AM	Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-03-25 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-20-24 03:27PM	First Solar, Frontier Communications, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-13-24 07:50AM	Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients (Benzinga) -31.33%
Dec-12-24 06:30PM	Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification (Business Wire)
Dec-10-24 07:00AM	Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts (Business Wire)
Dec-02-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-25-24 05:30PM	Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update (Business Wire)
Nov-13-24 10:39AM	Is Bicycle Therapeutics plc (BCYC) Top Performing European Stock Heading into 2025? (Insider Monkey)
Nov-12-24 07:00AM	Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-01-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-31-24 07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results (Business Wire)
Oct-23-24 07:00AM	Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals (Business Wire)
Oct-17-24 02:29PM	Bicycle Therapeutics (BCYC): High-Growth UK Stock with Innovative Peptide Technology (Insider Monkey)
Oct-16-24 07:00AM	Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress (Business Wire)
Oct-14-24 05:36AM	Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? (Zacks)
Oct-02-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-14-24 03:00AM	Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024 (Business Wire)
Sep-06-24 01:37PM	Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone (Benzinga)
Sep-03-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-21-24 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Aug-09-24 12:00PM	What Makes Bicycle Therapeutics (BCYC) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High? (Zacks)
Aug-06-24 01:53PM	BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +7.35%
07:05AM	Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results (Business Wire)
Aug-01-24 04:05PM	Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-22-24 07:00AM	Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024 (Business Wire) +6.94%
Jun-27-24 09:40AM	Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year? (Zacks)
Jun-11-24 09:40AM	Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-03-24 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
May-24-24 12:25PM	Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M (Zacks)
09:55AM	Wall Street Analysts Think Bicycle Therapeutics (BCYC) Could Surge 85.52%: Read This Before Placing a Bet (Zacks)
May-23-24 05:05PM	Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting (Business Wire) +9.62%
07:00AM	Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing (Business Wire)
May-21-24 09:40AM	Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year? (Zacks)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-06-24 12:00PM	Bicycle Therapeutics (BCYC) Moves to Buy: Rationale Behind the Upgrade (Zacks) -5.21%
09:55AM	Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High? (Zacks)
May-02-24 01:54PM	BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:44AM	Bicycle Therapeutics PLC (BCYC) Q1 2024 Earnings: Narrowing Losses Amidst Robust R&D Progress (GuruFocus.com)
07:00AM	Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results (Business Wire)
Apr-24-24 10:05AM	Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting (Business Wire)
Apr-02-24 07:00AM	Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-05-24 04:35PM	Bicycle Therapeutics to Present at the AACR Annual Meeting 2024 (Business Wire)
Feb-28-24 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Feb-20-24 07:05AM	Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-07-24 07:00AM	Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-05-24 02:02AM	Bicycle Therapeutics PLC CEO Kevin Lee Sells 8,703 Shares (GuruFocus.com)
Dec-14-23 07:00AM	Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day (Business Wire) -8.93%
Nov-30-23 07:00AM	Bicycle Therapeutics to Host R&D Day on December 14 (Business Wire) +6.51%
Nov-02-23 08:46AM	Bicycle Therapeutics PLC (BCYC) Reports Q3 2023 Financial Results and Upcoming R&D Day (GuruFocus.com)
07:00AM	Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results and Announces Upcoming R&D Day (Business Wire)
06:04AM	The Stage Is Set for a Rally: Canaccord Sees up to 290% Upside for These 3 Stocks (TipRanks)
Oct-30-23 07:00AM	Bicycle Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Oct-19-23 07:00AM	Bicycle Therapeutics Selected to Participate in FDA Program to Expedite Commercial Manufacturing Readiness of BT8009 for Metastatic Bladder Cancer (Business Wire)
04:00AM	Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director (GlobeNewswire)
Sep-14-23 10:12AM	Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates (Zacks)
Sep-12-23 07:54AM	Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up (Zacks) -7.27%
06:36AM	Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains? (Zacks)
Sep-11-23 02:19PM	Why Shares of Bicycle Therapeutics Were Rising on Monday (Motley Fool) +8.97%
07:00AM	Bicycle Therapeutics Announces Expedited Development Plan for BT8009 in Metastatic Bladder Cancer (Business Wire)
Sep-05-23 07:00AM	Bicycle Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-03-23 06:59AM	Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Jul-18-23 07:00AM	Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Swanton Robert Charles	Director	Oct 02 '26	Sale	3.47	3,431	11,906	15,782	Oct 06 04:45 PM
Skynner Michael	CHIEF SCIENTIFIC OFFICER	Oct 02 '26	Sale	3.47	1,942	6,739	155,229	Oct 06 04:45 PM
Skynner Michael	CHIEF SCIENTIFIC OFFICER	Oct 05 '26	Sale	3.57	503	1,796	154,726	Oct 06 04:45 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Oct 02 '26	Sale	3.47	1,572	5,455	92,803	Oct 06 04:45 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Oct 05 '26	Sale	3.57	242	864	92,561	Oct 06 04:45 PM
Perry Jennifer Scott	Chief Operating Officer	Oct 02 '26	Sale	3.47	1,094	3,796	89,958	Oct 06 04:45 PM
Perry Jennifer Scott	Chief Operating Officer	Oct 05 '26	Sale	3.74	406	1,517	89,552	Oct 06 04:45 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Oct 02 '26	Sale	3.47	6,167	21,399	597,504	Oct 06 04:45 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Oct 05 '26	Sale	3.57	1,638	5,848	595,866	Oct 06 04:45 PM
Thompson Travis Alvin	Chief Financial Officer	Oct 02 '26	Sale	3.47	893	3,099	64,528	Oct 06 04:34 PM
Thompson Travis Alvin	Chief Financial Officer	Oct 05 '26	Sale	3.57	79	282	64,449	Oct 06 04:34 PM
Lee Kevin	Officer	Oct 02 '26	Proposed Sale	3.47	9,000	31,231		Oct 02 04:07 PM
Perry Jennifer Scott	Chief Operating Officer	Jul 02 '26	Sale	4.27	1,036	4,424	91,428	Jul 07 05:00 PM
Perry Jennifer Scott	Chief Operating Officer	Jul 06 '26	Sale	4.34	376	1,631	91,052	Jul 07 05:00 PM
Skynner Michael	CHIEF SCIENTIFIC OFFICER	Jul 02 '26	Sale	4.27	1,859	7,938	157,703	Jul 07 05:00 PM
Skynner Michael	CHIEF SCIENTIFIC OFFICER	Jul 06 '26	Sale	4.31	532	2,293	157,171	Jul 07 05:00 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Jul 02 '26	Sale	4.27	5,905	25,214	605,408	Jul 07 05:00 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Jul 06 '26	Sale	4.31	1,737	7,486	603,671	Jul 07 05:00 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Jul 02 '26	Sale	4.27	1,506	6,431	94,630	Jul 07 05:00 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Jul 06 '26	Sale	4.31	255	1,099	94,375	Jul 07 05:00 PM
Thompson Travis Alvin	Chief Financial Officer	Jul 02 '26	Sale	4.27	819	3,497	64,545	Jul 07 05:00 PM
Thompson Travis Alvin	Chief Financial Officer	Jul 06 '26	Sale	4.31	104	448	64,441	Jul 07 05:00 PM
Lee Kevin	Officer	Jul 02 '26	Proposed Sale	4.27	8,000	34,155		Jul 02 04:09 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Apr 02 '26	Sale	4.91	1,521	7,468	96,387	Apr 06 06:30 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Apr 06 '26	Sale	5.05	251	1,268	96,136	Apr 06 06:30 PM
Thompson Travis Alvin	Chief Financial Officer	Apr 02 '26	Sale	4.91	799	3,923	65,466	Apr 06 06:30 PM
Thompson Travis Alvin	Chief Financial Officer	Apr 06 '26	Sale	5.05	102	515	65,364	Apr 06 06:30 PM
Perry Jennifer Scott	Chief Operating Officer	Apr 02 '26	Sale	4.91	1,038	5,097	92,834	Apr 06 06:30 PM
Perry Jennifer Scott	Chief Operating Officer	Apr 06 '26	Sale	5.04	370	1,865	92,464	Apr 06 06:30 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Apr 02 '26	Sale	4.91	5,967	29,298	613,029	Apr 06 06:30 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Apr 06 '26	Sale	5.05	1,716	8,666	611,313	Apr 06 06:30 PM
Skynner Michael	CHIEF SCIENTIFIC OFFICER	Apr 02 '26	Sale	4.91	1,879	9,226	160,087	Apr 06 06:30 PM
Skynner Michael	CHIEF SCIENTIFIC OFFICER	Apr 06 '26	Sale	5.05	525	2,651	159,562	Apr 06 06:30 PM
Young Alethia	Officer	Apr 02 '26	Proposed Sale	4.91	2,034	9,977		Apr 02 05:39 PM
Perry Jennifer Scott	Officer	Apr 02 '26	Proposed Sale	4.91	1,500	7,358		Apr 02 05:27 PM
Thompson Travis Alvin	Officer	Apr 02 '26	Proposed Sale	4.91	1,000	4,905		Apr 02 05:18 PM
Hannay Michael Charles Ferguso	Officer	Apr 02 '26	Proposed Sale	4.91	1,850	9,075		Apr 02 05:09 PM
Milnes Alistair	Officer	Apr 02 '26	Proposed Sale	4.91	2,850	13,980		Apr 02 04:57 PM
Skynner Michael	Officer	Apr 02 '26	Proposed Sale	4.91	2,500	12,263		Apr 02 04:51 PM
Lee Kevin	Officer	Apr 02 '26	Proposed Sale	4.91	8,000	39,242		Apr 02 04:27 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Jan 02 '26	Sale	6.80	1,317	8,956	67,380	Jan 06 08:00 PM
Thompson Travis Alvin	CHIEF ACCOUNTING OFFICER	Jan 05 '26	Sale	6.45	1,115	7,192	66,265	Jan 06 08:00 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Jan 05 '26	Sale	6.46	3,266	21,098	161,966	Jan 06 08:00 PM
Skynner Michael	CHIEF TECHNOLOGY OFFICER	Jan 02 '26	Sale	6.80	3,045	20,706	165,232	Jan 06 08:00 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Jan 02 '26	Sale	6.80	2,827	19,224	100,275	Jan 06 08:00 PM
Hannay Michael Charles Ferguso	CHIEF PROD & SUPPLY CHAIN OFF	Jan 05 '26	Sale	6.45	2,367	15,267	97,908	Jan 06 08:00 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Jan 05 '26	Sale	6.46	3,416	22,067	136,717	Jan 06 08:00 PM
Milnes Alistair	CHIEF OPERATING OFFICER	Jan 02 '26	Sale	6.80	3,244	22,059	140,133	Jan 06 08:00 PM
Young Alethia	Chief Financial Officer	Jan 05 '26	Sale	6.49	4,334	28,123	87,081	Jan 06 08:00 PM
Young Alethia	Chief Financial Officer	Jan 02 '26	Sale	6.80	3,289	22,365	91,415	Jan 06 08:00 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Jan 05 '26	Sale	6.46	10,989	70,989	618,996	Jan 06 08:00 PM
Lee Kevin	CHIEF EXECUTIVE OFFICER	Jan 02 '26	Sale	6.80	10,325	70,210	629,985	Jan 06 08:00 PM
Young Alethia	Officer	Jan 05 '26	Proposed Sale	6.53	123	803		Jan 05 04:29 PM
Milnes Alistair	Officer	Jan 02 '26	Proposed Sale	6.94	6,750	46,850		Jan 02 04:46 PM
Skynner Michael	Officer	Jan 02 '26	Proposed Sale	6.80	6,400	43,507		Jan 02 04:44 PM
Thompson Travis Alvin	Officer	Jan 02 '26	Proposed Sale	6.80	2,750	18,695		Jan 02 04:37 PM
Young Alethia	Officer	Jan 02 '26	Proposed Sale	6.80	7,500	50,985		Jan 02 04:36 PM
Hannay Michael Charles Ferguso	Officer	Jan 02 '26	Proposed Sale	6.80	5,250	35,690		Jan 02 04:35 PM
Lee Kevin	Officer	Jan 02 '26	Proposed Sale	6.80	21,500	146,157		Jan 02 04:31 PM

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Ph.D.Dr. Kevin Lee M.B.A.

Ph.D.Dr. Michael Skynner B.sc. Ph.d.

Chief Corporate Development OfficerMr. Alistair Milnes

Scientific FounderDr. Christian Heinis

Chief Financial OfficerMr. Travis Thompson

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Bicycle Therapeutics Plc ADR

Upgrade your Finviz experience